Q2 2014 · —
Revenue$21.00K$21.00K −84.2% vs Q2 2013−87.7% vs Q1 2014
Net Income-$16.43M-$16.43M no prior Q2 2013 on fileN/M vs Q1 2014
EPS Diluted-$0.55-$0.55 N/M vs Q2 2013N/M vs Q1 2014
Operating Income-$16,448,000N/M
Operating Cash Flowderived-$11,882,000N/M
Free Cash Flowderived-$12,206,000—
Margins · derived
Operating margin-78323.8%−73158.4 pt vs Q2 2013
Net margin-78242.9%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2014 | Q2 2013 | Q2 2012 |
|---|---|---|---|
| Revenue | $21.00K | $133.00K | $533.00K |
| Net Income | -$16.43M | — | — |
| EPS Diluted | -$0.55 | -$2.86 | -$2.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR